Warren Buffett's Berkshire Hathaway (NYSE:BRK-B) just made a rather surprising bet on shares of AI titan Alphabet (NASDAQ:GOOG) last quarter. ...

Core Insights - Clearmind Medicine Inc. announced positive top-line results from its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2] - The trial demonstrated a favorable safety profile with no serious adverse events and high treatment adherence among participants, indicating the potential for CMND-100 as a breakthrough therapy for AUD [2][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [5] - The company holds a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Clinical Trial Details - The first cohort of the trial included six patients, treated at prestigious institutions such as Johns Hopkins University and Yale University, under an FDA-approved protocol [3] - The trial is designed to assess the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in individuals with heavy binge drinking or AUD [3] Executive Commentary - The CEO of Clearmind expressed enthusiasm regarding the initial results, highlighting the encouraging safety profile and treatment observance, which support the company's goal of pioneering therapies for addiction [4]

Core Insights - Team, Inc. (TISI) shares have decreased by 6.3% following the third-quarter 2025 results, contrasting with a 1.9% decline in the S&P 500 index, although the stock has increased by 11.4% over the past month, indicating improved investor sentiment [1] Financial Performance - Revenues for the quarter rose by 6.7% year-over-year to $225 million, with gross margin expanding by 8.4% to $58 million, and adjusted EBITDA increasing by 28.6% to $14.5 million, leading to a margin improvement of 110 basis points [2] - The net loss was reported at $11.4 million, slightly higher than the $11.1 million loss from the previous year, with earnings per share reflecting a loss of $2.68 compared to a loss of $2.52 last year [2] Segment Performance - The Inspection & Heat-Treating (IHT) segment generated revenues of $113.8 million, a 5.7% increase, driven by higher service activity in the U.S. and an 8.9% increase in international markets [3] - The Mechanical Services (MS) segment saw revenues improve by 7.8% to $111.2 million, supported by stronger U.S. turnaround activity and better results in Canada, with operating income rising by 31.2% to $5.9 million [3] Cost Management - Adjusted selling, general and administrative expenses decreased to 20.8% of revenues from 21.7% in the prior-year quarter, indicating progress in cost control, although corporate expenses increased due to non-recurring legal fees, compressing consolidated operating income to $1.3 million from $3.2 million [4] Management Commentary - Management noted that adjusted EBITDA reached its highest level for a third quarter since at least 2016, with growth in adjusted EBITDA outpacing revenue gains, reflecting successful cost-reduction and margin-expansion initiatives [5] - The company is focused on maintaining cost discipline, enhancing commercial execution in higher-margin markets, and expanding wallet share among existing customers, with ongoing improvements in margin and cost structure simplification [6] Revenue Drivers - Revenue growth was primarily driven by volume gains in both core segments, with IHT benefiting from increased U.S. activity and international work, while MS saw elevated demand in the U.S. and improved Canadian activity [7] Cost Factors - Margin improvements were attributed to field cost rationalization and a better project mix, although consolidated operating income contracted due to higher non-recurring corporate expenses [8] Guidance - Management expects full-year 2025 revenue growth of approximately 5% and adjusted EBITDA growth of roughly 13%, with anticipated year-over-year gains in the fourth quarter and further improvements in international operations [10] Other Developments - Team completed a $75 million private placement of preferred stock, using proceeds to reduce total debt from $325.1 million to $302.8 million, enhancing liquidity and financial flexibility [11]

Company Performance - Medtronic reported quarterly earnings of $1.36 per share, exceeding the Zacks Consensus Estimate of $1.31 per share, and up from $1.26 per share a year ago, representing an earnings surprise of +3.82% [1] - The company posted revenues of $8.96 billion for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 1.11%, compared to $8.4 billion in the same quarter last year [2] - Medtronic has surpassed consensus EPS estimates in all four of the last quarters and topped consensus revenue estimates three times during the same period [2] Stock Performance - Medtronic shares have increased approximately 20.5% since the beginning of the year, outperforming the S&P 500's gain of 13.4% [3] - The current consensus EPS estimate for the upcoming quarter is $1.35 on revenues of $8.83 billion, and for the current fiscal year, it is $5.63 on revenues of $35.8 billion [7] Industry Outlook - The Medical - Products industry, to which Medtronic belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Medtronic's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025. “The third quarter was marked by solid and positive clinical and operational execution. Our clinical, manufacturing and regulatory teams are heavily focused on moving Ampligen down a pathway toward eventual FDA approval as part of a combination therapy for pancreatic cancer. We recently reported posit ...

We invest thousands of hours and over $100,000 annually researching the most profitable opportunities—all to bring you real estate strategies at a fraction of the cost. Limited Time Only: Get $100 Off! Our approach has earned us over 500 five-star reviews from satisfied members already seeing results. Your timing is perfect. We've just released our top investment picks for 2026, and for a limited time, you can join High Yield Landlord for $100 off. Offer ends soon—join now to claim your $100 discount and st ...

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed abo ...

Lawrence Fuller is the Principal of Fuller Asset Management (FAM), a state registered investment adviser. He is also the manager of the Focused Growth portfolio on the copy-trading platform Dubapp.com. Information presented is for educational purposes only intended for a broad audience. The information does not intend to make an offer or solicitation for the sale of purchase of any specific securities, investments, or investment strategies. Investments involve risk and are not guaranteed. FAM has reasonable ...

Key Takeaways Bank of America (BAC) unveiled a new medium-term return on tangible common equity (ROTCE) target of 16-18% during its Investor Day conference. The bank's pursuit of reaching the ROTCE target forms a clear, credible investment case anchored in revenue expansion, operating discipline and stronger client engagement. Management is targeting 5-7% organic net interest income expansion, underpinned by steady mid-single-digit loan and deposit growth across the franchise. A major earnings catalyst is t ...

Key Takeaways JPMorgan (JPM) delivered another strong quarter, extending its streak of high-single-digit revenue growth. In the third quarter of 2025, total revenues rose 9% year over year, underscoring the firm's diversification across markets, banking, asset management and payments, supported by resilient macro conditions and a constructive regulatory backdrop. In recent quarters, JPM's momentum has been broad-based. Net interest income (NII) continued to benefit from higher card revolver balances and hea ...